Safety concerns exist when using triptansto treat patients with cardiac contraindications.
–Triptans cause vasoconstriction, a safety concern for migraineurswith cardiovascular (CV) disease or other cardiac risk factors.
–All triptans contain contraindications in their package inserts to avoid use in patients with cardiac conditions.
•Previous research indicates that clinicians are less likely to prescribe triptansin patients with CV disease or CV risk factors.
Limited research has examined the proportion of migraine patients with cardiovascular disease or those individuals who were concurrently treated with triptans.
Recommended CitationNg-Mak, PhD, Daisy; Pracilio, MPH, Valerie P.; Silberstein, MD, Stephen; Couto, PharmD, MBA, Joseph; Sennett, MD, PhD, Cary; Hopkins, RN, Mary; Bumbaugh, Jon; and Goldfarb, Neil I., "Association between TriptanUse and Cardiac Contraindications in an Insured Migraine Population" (2012). School of Population Health Lectures, Presentations, Workshops. Paper 23.